BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 33831328)

  • 1. Long-term efficacy and safety of botulinum toxin treatment for cervical dystonia: a critical reappraisal.
    Marsili L; Bologna M; Jankovic J; Colosimo C
    Expert Opin Drug Saf; 2021 Jun; 20(6):695-705. PubMed ID: 33831328
    [No Abstract]   [Full Text] [Related]  

  • 2. The clinical utility of botulinum toxin injections targeted at the motor endplate zone in cervical dystonia.
    Delnooz CC; Veugen LC; Pasman JW; Lapatki BG; van Dijk JP; van de Warrenburg BP
    Eur J Neurol; 2014 Dec; 21(12):1486-e98. PubMed ID: 25060697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse events with botulinum toxin treatment in cervical dystonia: How much should we blame placebo?
    Duarte GS; Rodrigues FB; Ferreira JJ; Costa J
    Parkinsonism Relat Disord; 2018 Nov; 56():16-19. PubMed ID: 29910156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
    Pappert EJ; Germanson T;
    Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-Dose Neubotulinum Toxin A versus Low-Dose Abobotulinum Toxin A Injection for the Treatment of Cervical Dystonia: A Multicenter, 48-Week, Prospective, Double-Blinded, Randomized Crossover Design Study.
    Kongsaengdao S; Arayawithchanont A; Samintharapanya K; Rojanapitayakorn P; Maneeton B; Maneeton N
    Toxins (Basel); 2021 Oct; 13(10):. PubMed ID: 34678987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials.
    Chinnapongse RB; Lew MF; Ferreira JJ; Gullo KL; Nemeth PR; Zhang Y
    Clin Neuropharmacol; 2012; 35(5):215-23. PubMed ID: 22932474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of cervical dystonia with abo- and onabotulinumtoxinA: long-term safety and efficacy in daily clinical practice.
    Jochim A; Meindl T; Mantel T; Zwirner S; Zech M; Castrop F; Haslinger B
    J Neurol; 2019 Aug; 266(8):1879-1886. PubMed ID: 31049731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of the Course of Disease before Botulinum Toxin Therapy on the Course of Treatment and Long-Term Outcome in Cervical Dystonia.
    Hefter H; Schomaecker I; Schomaecker M; Rosenthal D; Samadzadeh S
    Toxins (Basel); 2021 Jul; 13(7):. PubMed ID: 34357965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the Interplay between the Clinical and Presumed Effect of Botulinum Injections for Cervical Dystonia: A Pilot Study.
    Hefter H; Samadzadeh S
    Toxins (Basel); 2023 Sep; 15(10):. PubMed ID: 37888623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized botulinum toxin type A therapy for cervical dystonia based on kinematic guidance.
    Samotus O; Lee J; Jog M
    J Neurol; 2018 Jun; 265(6):1269-1278. PubMed ID: 29557988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
    Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD
    Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin therapy for cervical dystonia.
    Jankovic J
    Neurotox Res; 2006 Apr; 9(2-3):145-8. PubMed ID: 16785112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group.
    Kessler KR; Skutta M; Benecke R
    J Neurol; 1999 Apr; 246(4):265-74. PubMed ID: 10367694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum toxin type B for cervical dystonia.
    Costa J; Espírito-Santo C; Borges A; Ferreira JJ; Coelho M; Moore P; Sampaio C
    Cochrane Database Syst Rev; 2005 Jan; (1):CD004315. PubMed ID: 15674941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of botulinum toxin in pregnancy and its impact on female reproductive health.
    Li W; Tang M
    Expert Opin Drug Saf; 2020 Jan; 19(1):83-91. PubMed ID: 31868020
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia.
    Factor SA; Molho ES; Evans S; Feustel PJ
    Mov Disord; 2005 Sep; 20(9):1152-60. PubMed ID: 15954134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relevance of sonography for botulinum toxin treatment of cervical dystonia: an expert statement.
    Schramm A; Bäumer T; Fietzek U; Heitmann S; Walter U; Jost WH
    J Neural Transm (Vienna); 2015 Oct; 122(10):1457-63. PubMed ID: 25547861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing secondary non-response to botulinum toxin type A injections in cervical dystonia.
    Ferreira JJ; Colosimo C; Bhidayasiri R; Marti MJ; Maisonobe P; Om S
    Parkinsonism Relat Disord; 2015 Feb; 21(2):111-5. PubMed ID: 25499753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.
    Brin MF; Lew MF; Adler CH; Comella CL; Factor SA; Jankovic J; O'Brien C; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
    Neurology; 1999 Oct; 53(7):1431-8. PubMed ID: 10534247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum neurotoxin a therapy efficacy and safety for oromandibular dystonia: a meta-analysis.
    Dadgardoust PD; Rosales RL; Asuncion RM; Dressler D
    J Neural Transm (Vienna); 2019 Feb; 126(2):141-148. PubMed ID: 30604200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.